{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T13:24:17Z","timestamp":1761744257993},"reference-count":24,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100010877","name":"ViiV Healthcare","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100010877","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica"],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.1016\/j.eimc.2016.02.029","type":"journal-article","created":{"date-parts":[[2016,4,7]],"date-time":"2016-04-07T10:16:17Z","timestamp":1460024177000},"page":"493-498","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Hepatic safety of maraviroc in HIV-1-infected patients with hepatitis C and\/or B co-infection. The Maraviroc Cohort Spanish Group"],"prefix":"10.1016","volume":"35","author":[{"given":"Manuel","family":"Crespo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jordi","family":"Navarro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Santiago","family":"Moreno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jesus","family":"Sanz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manuel","family":"M\u00e1rquez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javier","family":"Zamora","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Ocampo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 A.","family":"Iribaren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Rivero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Josep M.","family":"Llibre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1 (Suppl.)","key":"10.1016\/j.eimc.2016.02.029_bib0130","doi-asserted-by":"crossref","first-page":"S132","DOI":"10.1016\/j.jhep.2005.11.027","article-title":"Hepatotoxicity of antiretrovirals: incidence, mechanisms and management","volume":"44","author":"Nunez","year":"2006","journal-title":"J. Hepatol."},{"key":"10.1016\/j.eimc.2016.02.029_bib0135","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1016\/S0140-6736(14)60084-2","article-title":"Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study","volume":"383","author":"Clotet","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.eimc.2016.02.029_bib0140","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S0140-6736(12)61853-4","article-title":"Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study","volume":"381","author":"Raffi","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.eimc.2016.02.029_bib0145","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1056\/NEJMoa1215541","article-title":"Dolutegravir plus abacavir\u2013lamivudine for the treatment of HIV-1 infection","volume":"369","author":"Walmsley","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.eimc.2016.02.029_bib0150","doi-asserted-by":"crossref","first-page":"e118","DOI":"10.1097\/QAI.0000000000000057","article-title":"A randomized, double-blind comparison of single-tablet regimen elvitegravir\/cobicistat\/emtricitabine\/tenofovir DF versus single-tablet regimen efavirenz\/emtricitabine\/tenofovir DF for initial treatment of HIV-1 infection: analysis of week 144 results","volume":"65","author":"Wohl","year":"2014","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"10.1016\/j.eimc.2016.02.029_bib0155","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1177\/135965350801300204","article-title":"Antiviral activity and safety of aplaviroc with lamivudine\/zidovudine in HIV-infected, therapy-naive patients: the ASCENT (CCR102881) study","volume":"13","author":"Currier","year":"2008","journal-title":"Antiviral Ther."},{"key":"10.1016\/j.eimc.2016.02.029_bib0160","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.1097\/QAD.0b013e32833f9ce2","article-title":"Hepatic safety and tolerability in the maraviroc clinical development program","volume":"24","author":"Ayoub","year":"2010","journal-title":"Aids"},{"key":"10.1016\/j.eimc.2016.02.029_bib0165","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1179\/1528433614Z.0000000002","article-title":"The maraviroc expanded access program \u2013 safety and efficacy data from an open-label study","volume":"16","author":"Lazzarin","year":"2015","journal-title":"HIV Clin. Trials"},{"key":"10.1016\/j.eimc.2016.02.029_bib0175","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/j.jhep.2012.06.010","article-title":"All-cause and liver-related mortality in HIV positive subjects compared to the general population: differences by HCV co-infection","volume":"57","author":"Hernando","year":"2012","journal-title":"J. Hepatol."},{"key":"10.1016\/j.eimc.2016.02.029_bib0180","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1053\/j.gastro.2014.06.043","article-title":"Roles for chemokines in liver disease","volume":"147","author":"Marra","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.eimc.2016.02.029_bib0185","first-page":"1858","article-title":"CCR1 and CCR5 promote hepatic fibrosis in mice","volume":"119","author":"Seki","year":"2009","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.eimc.2016.02.029_bib0190","doi-asserted-by":"crossref","first-page":"4129","DOI":"10.1172\/JCI41732","article-title":"Antagonism of the chemokine Ccl5 ameliorates experimental liver fibrosis in mice","volume":"120","author":"Berres","year":"2010","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.eimc.2016.02.029_bib0195","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1002\/hep.26403","article-title":"Inflammation-induced hepatocellular carcinoma is dependent on CCR5 in mice","volume":"58","author":"Barashi","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.eimc.2016.02.029_bib0200","doi-asserted-by":"crossref","first-page":"e53992","DOI":"10.1371\/journal.pone.0053992","article-title":"Maraviroc, a CCR5 antagonist, prevents development of hepatocellular carcinoma in a mouse model","volume":"8","author":"Ochoa-Callejero","year":"2013","journal-title":"PLOS ONE"},{"key":"10.1016\/j.eimc.2016.02.029_bib0205","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1093\/jac\/dku071","article-title":"Maraviroc, a CCR5 antagonist, ameliorates the development of hepatic steatosis in a mouse model of non-alcoholic fatty liver disease (NAFLD)","volume":"69","author":"Perez-Martinez","year":"2014","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.eimc.2016.02.029_bib0210","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.antiviral.2015.05.001","article-title":"Safety, efficacy and indications of prescription of maraviroc in clinical practice: factors associated with clinical outcomes","volume":"120","author":"Llibre","year":"2015","journal-title":"Antiviral Res."},{"key":"10.1016\/j.eimc.2016.02.029_bib0215","unstructured":"DAIDS table for grading the severity of adult and pediatric adverse events. Available at: http:\/\/rsc.tech-res.com\/safetyandpharmacovigilance\/gradingtables.aspx (accessed September 21)."},{"key":"10.1016\/j.eimc.2016.02.029_bib0220","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1002\/hep.21178","article-title":"Development of a simple noninvasive index to predict significant fibrosis in patients with HIV\/HCV coinfection","volume":"43","author":"Sterling","year":"2006","journal-title":"Hepatology"},{"key":"10.1016\/j.eimc.2016.02.029_bib0225","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1056\/NEJMoa0803152","article-title":"Maraviroc for previously treated patients with R5 HIV-1 infection","volume":"359","author":"Gulick","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.eimc.2016.02.029_bib0230","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1097\/QAI.0b013e3181ee3d82","article-title":"Two-year safety and virologic efficacy of maraviroc in treatment-experienced patients with CCR5-tropic HIV-1 infection: 96-week combined analysis of MOTIVATE 1 and 2","volume":"55","author":"Hardy","year":"2010","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"10.1016\/j.eimc.2016.02.029_bib0235","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1097\/QAI.0b013e3182a7a97a","article-title":"Five-year safety evaluation of maraviroc in HIV-1-infected treatment-experienced patients","volume":"65","author":"Gulick","year":"2014","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"10.1016\/j.eimc.2016.02.029_bib0240","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1179\/1528433614Z.0000000011","article-title":"Hepatic safety in subjects with HIV-1 and hepatitis C and\/or B virus: a randomized, double-blind study of maraviroc versus placebo in combination with antiretroviral agents","volume":"16","author":"Rockstroh","year":"2015","journal-title":"HIV Clin. Trials"},{"key":"10.1016\/j.eimc.2016.02.029_bib0245","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1097\/QAD.0b013e328013db9c","article-title":"Is the increased risk of liver enzyme elevation in patients co-infected with HIV and hepatitis virus greater in those taking antiretroviral therapy?","volume":"21","author":"Cicconi","year":"2007","journal-title":"Aids"},{"key":"10.1016\/j.eimc.2016.02.029_bib0250","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1002\/hep.22134","article-title":"Steatohepatitis: risk factors and impact on disease severity in human immunodeficiency virus\/hepatitis C virus coinfection","volume":"47","author":"Sterling","year":"2008","journal-title":"Hepatology"}],"container-title":["Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0213005X16300283?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0213005X16300283?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T07:39:09Z","timestamp":1655451549000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0213005X16300283"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10]]},"references-count":24,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2017,10]]}},"alternative-id":["S0213005X16300283"],"URL":"https:\/\/doi.org\/10.1016\/j.eimc.2016.02.029","relation":{},"ISSN":["0213-005X"],"issn-type":[{"value":"0213-005X","type":"print"}],"subject":[],"published":{"date-parts":[[2017,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hepatic safety of maraviroc in HIV-1-infected patients with hepatitis C and\/or B co-infection. The Maraviroc Cohort Spanish Group","name":"articletitle","label":"Article Title"},{"value":"Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eimc.2016.02.029","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Espa\u00f1a, S.L.U. and Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. All rights reserved.","name":"copyright","label":"Copyright"}]}}